Share on StockTwits

AbbVie (NASDAQ:ABBV) has earned an “A-” credit rating from Morningstar. The agency’s “A-” rating indicates that the company is a low default risk. They also issued a negative credit outlook for the company and gave their stock a three star rating.

A number of other firms have also recently commented on ABBV. Analysts at Credit Suisse raised their price target on shares of AbbVie from $60.00 to $63.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of AbbVie in a research note on Monday, July 28th. They now have a $56.00 price target on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of AbbVie from $68.00 to $72.00 in a research note on Monday, July 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. AbbVie currently has an average rating of “Buy” and a consensus target price of $62.80.

Shares of AbbVie (NASDAQ:ABBV) traded down 0.58% during mid-day trading on Monday, hitting $55.28. 7,524,434 shares of the company’s stock traded hands. AbbVie has a one year low of $42.31 and a one year high of $58.27. The stock has a 50-day moving average of $54.03 and a 200-day moving average of $52.83. The company has a market cap of $87.989 billion and a price-to-earnings ratio of 21.55.

AbbVie (NASDAQ:ABBV) last issued its quarterly earnings data on Friday, July 25th. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.76 by $0.06. The company had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.70 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Analysts expect that AbbVie will post $3.16 EPS for the current fiscal year.

AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.

To view more credit ratings from Morningstar, visit

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.